Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IFNAR1 | P17181 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | MC5R | P33032 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MC1R | Q01726 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434746 | 1.00 | IFNAR1 (0.66) | IFNAR1CA2CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL5321295 | 1.00 | IFNAR1 (0.66) | IFNAR1CA2CYP1A2CYP2C19CYP2D6 | |
| Hydrochloric Acid SCHEMBL6251238 | 0.98 | IFNAR1 (0.64) | IFNAR1CA2CYP1A2CYP2C19CYP2D6 | |
| Hydrochloric Acid SCHEMBL1093699 | 0.98 | IFNAR1 (0.64) | IFNAR1CA2CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL14110952 | 0.86 | IFNAR1 (0.51) | IFNAR1CA2CYP1A2CYP2C19CYP2D6 | |
| Isophthalic Acid SCHEMBL27488646 | 0.82 | POLB (0.54) | IFNAR1LMNARECQLSMN1; SMN2MEN1 | |
| SCHEMBL6008064 | 0.82 | MC5R (0.70) | CA2CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL3144929 | 0.82 | IFNAR1 (0.51) | IFNAR1CA2MC5RMAPK1LMNA | |
| SCHEMBL19144969 | 0.80 | CA2 (0.56) | CA2CYP1A2CYP2C19CYP2D6CYP2C9 | |
| SCHEMBL30996076 | 0.80 | IFNAR1 (1.00) | IFNAR1CYP1A2CYP2C19CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 516 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120117949-A | Method for directly preparing tertiary amine compound from aromatic aldehyde, ketone and secondary amine | 湖南大学 | 2025-06-10 | — | — | CN | claimed |
| CN-115073303-B | Preparation method of terbinafine hydrochloride Z-type isomer | 乐泰药业(兰西)有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-113493388-B | Synthesis method of butenafine hydrochloride | 鲁南制药集团股份有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-113979871-B | Preparation method of N-methyl-1-naphthylmethylamine and intermediate N-methyl-1-naphthylmethylamine | 江苏同禾药业有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-112209838-B | Preparation method of butenaphthol hydrochloride | 鲁南制药集团股份有限公司 | 2023-02-17 | — | — | CN | claimed |
| CN-114380696-B | Preparation method of terbinafine hydrochloride | 山东诚汇双达药业有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-112552182-B | New synthesis process of naftifine drug intermediate N-methyl-1-naphthylmethylamine | 杭州新桂实业有限公司 | 2022-10-11 | — | — | CN | claimed |
| CN-115073303-A | Preparation method of terbinafine hydrochloride Z-type isomer | 乐泰药业(兰西)有限公司 | 2022-09-20 | — | — | CN | claimed |
| CN-114380696-A | Preparation method of terbinafine hydrochloride | 山东诚汇双达药业有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-110423200-B | Method for improving purity of terbinafine hydrochloride | 成都奥邦药业有限公司 | 2022-03-25 | — | — | CN | claimed |
| EP-1458668-A1 | PROCESS FOR PREPARING TERBINAFINE AND HCI SALT THEREOF | YUHAN CORPORATION, LTD. (KR) | 2004-09-22 | — | — | EP | claimed |
| US-6689913-B2 | REDUCTIVE ALKYLATION OF THE REACTION PRODUCT OF AN S-SUBSTITUTED-C-TERT-BUTYL-N-SULFONYLHYDRAZONYLFURAN AND A BASE WITH N-METHYL-1-NAPHTHALENEMETHYLAMINE OR ITS HCL SALT | YUHAN CORPORATION (KR) | 2004-02-10 | — | — | US | claimed |
| US-20030130530-A1 | Process for preparing terbinafine and HCI salt thereof | YUHAN CORPORATION (KR) | 2003-07-10 | — | — | US | claimed |
| WO-2003055844-A1 | PROCESS FOR PREPARING TERBINAFINE AND HCI SALT THEREOF | YUHAN CORPORATION (KR) | 2003-07-10 | — | — | WO | claimed |
| EP-1143950-A3 | TOPICAL APPLICATION PRODUCTS | IPR-Institute for Pharmaceutical Research AG (CH) | 2002-05-15 | — | — | EP | claimed |
| WO-2001077064-A1 | METHOD FOR THE PREPARATION OF (E)-N-(6,6-DIMETHYL-2-HEPTEN-4-YNYL)-N-METHYL-1-NAPHTHALENEMETHANAMINE (TERBINAFINE) | SLOVAKOFARMA A.S. (SK) | 2001-10-18 | — | — | WO | claimed |
| EP-1143950-A2 | TOPICAL APPLICATION PRODUCTS | IPR-Institute for Pharmaceutical Research AG (CH) | 2001-10-17 | — | — | EP | claimed |
| WO-2000015202-A2 | TOPICAL APPLICATION PRODUCTS | IPR-INSTITUTE FOR PHARMACEUTICAL RESEARCH AG (CH) | 2000-03-23 | — | — | WO | claimed |
| US-5817875-A | Methods for the manufacture of terbinafine | KARIMIAN KHASHAYAR (CA) | 1998-10-06 | — | — | US | claimed |
| EP-0363326-A2 | Fungicidal amines | SANDOZ AG (CH) | 1990-04-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130530-A1 | Process for preparing terbinafine and HCI salt thereof | TPMT, HNMT, BHMT | IFNAR1 1122/4885CA2 3960/4885CYP1A2 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.